Azafaros has raised €132 million in an oversubscribed Series B financing round. The funding will support the advancement of its lead clinical-stage asset, AZ-3102, into two Phase 3 trials for the treatment of rare lysosomal storage disorders: GM1 and GM2 gangliosidosis.
This significant milestone marks one of the largest private biotech financings in Europe so far in 2025. The round was led by Forbion Growth and included new investors such as Sofinnova Partners, as well as strategic investor Sarepta Therapeutics, alongside existing investors.
With this financing, Azafaros is poised to accelerate late-stage development of innovative therapies that target multiple neurological symptoms of rare genetic diseases, bringing new hope to patients and families affected by these devastating conditions.
Read more here
VarmX, a biotechnology company based at the Leiden Bio Science Park (LBSP), has entered into a strategic collaboration and option agreement with global biotechnology leader CSL...
Leiden University Medical Center (LUMC), via its Cairelab initiative, together with the Dutch Police, have been declared winners of the National AI Challenge 2025, organized by...
Marieke Vinkenoog and Simon Christian Hansmann have been awarded the Krijn Rietveld Memorial Innovation Awards for their research in blood donation and colorectal cancer. Vinkenoog’s work on predictive modeling for donor eligibility and Hansmann’s identification of cancer cells linked to tumor recurrence exemplify the integration of advanced scientific methods to address pressing health challenges.